BiotechTube

Caprelsa

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Medullary Thyroid Cancer

Conditions

Metastatic Medullary Thyroid Cancer

Trial Timeline

Apr 1, 2014 → Jun 1, 2015

NCT ID
NCT02109250

About Caprelsa

Caprelsa is a pre-clinical stage product being developed by Sanofi for Metastatic Medullary Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02109250. Target conditions include Metastatic Medullary Thyroid Cancer.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT02109250Pre-clinicalCompleted

Competing Products

20 competing products in Metastatic Medullary Thyroid Cancer

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
25
AbemaciclibEli LillyPre-clinical
23
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
77
SYNB1891 + AtezolizumabSynlogicPhase 1
25
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 3
77
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 1/2
41
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Induction therapyChugai PharmaceuticalPhase 2
52
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelinChugai PharmaceuticalPhase 2
52
bevacizumab + PaclitaxelChugai PharmaceuticalPhase 2
52
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
52
GC33Chugai PharmaceuticalPhase 1
33
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
DS9051bDaiichi SankyoPhase 1
33

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84